Angiotech Pharmaceuticals, Inc.

Industry

  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Consumables, Central Supplies
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Infection Control-Sterilization
    • Biomaterials
    • Laser
    • Radiofrequency Devices
    • Rehabilitation Equipment and Devices
    • Infusion Therapy Equipment and Supplies
  • Biotechnology
  • Pharmaceuticals

Other Names/Subsidiaries

  • Quill Medical Inc.
  • Surgical Specialties Corporation, Inc.
See more in Biomedtracker

Latest on Angiotech Pharmaceuticals, Inc.

Scrip

J&J's Yondelis Leads New Wave Of Sarcoma Drugs

 
• By Emily Hayes

Johnson & Johnson's long-awaited chemotherapy Yondelis (trabedectin) is finally approved for sarcoma in the US, having been approved in multiple other markets already, but leading a wave of potentia

Medtech Insight

Medtech Execs On The Move, November-December 2014

Company Changes BARR , John To: Angiotech Pharmaceuticals Inc. , CEO (October) From: Bausch & Lomb Inc., EVP, Pres., Global Surgical Phone: 604-221-7676 BARTHELEMY , Nicolas To: bioTheranos

In Vivo

Execs On The Move, November 2014

New At The Helm Company Changes BAKER , David To: Sensory Medical Inc. , Pres. & CEO (September) From: MyCardio LLC, CEO Phone: 888-721-1117 BARR , John R. To: Angiotech Pharmaceuticals Inc

Scrip

JnJ/Janssen seek US Yondelis OK in soft tissue sarcoma

 
• By Donna Young

Johnson & Johnson subsidiary Janssen Research & Development is seeking the FDA's approval to market Yondelis (trabectedin), a multimodal synthetically produced antitumor agent, originally derived from